EGFR and non-small cell lung carcinoma: The lower incidence of on-target resistance to osimertinib possibly reflects better on-target inhibition and discrepancy in selective pressure and/or clonal evolution of EGFR-mutated NSCLC compared with early-generation EGFR-TKIs [59].